SWM
NVCR icon

SeaCrest Wealth Management’s NovoCure NVCR Stock Holding History

SeaCrest Wealth Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-227
Closed -$11K – 1398
2019
Q1 		$11K Hold
227
– – ﹤0.01% 1500
2018
Q4 		$8K Buy
+227
New +$8.3K ﹤0.01% 1559

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCP
Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SeaCrest Wealth Management's NVCR Position: Q2 2019 in Review

SeaCrest Wealth Management sold out of NovoCure (NVCR) in Q2 2019, closing a stake of 227 shares — an estimated $11K sold.

SeaCrest Wealth Management first reported a position in NVCR in Q4 2018 and held it in 2 quarters. The position peaked at $11K in Q1 2019. 197 funds tracked by Wall St. Rank hold NVCR as of Q2 2019.

  • SeaCrest Wealth Management reported no remaining NovoCure position as of Q2 2019 after selling out during the quarter.
  • SeaCrest Wealth Management sold 227 NovoCure shares in Q2 2019, an estimated $11K.
  • SeaCrest Wealth Management first reported a position in NovoCure in Q4 2018 and held it in 2 quarters.
  • SeaCrest Wealth Management's NovoCure position peaked at $11K in Q1 2019.
  • 197 funds tracked by Wall St. Rank held NovoCure as of Q2 2019.

Based on SeaCrest Wealth Management's 13F filing for Q2 2019, filed 19 Jul 2019.